Fas receptor expression on peripheral blood T lymphocytes in patients with secondary progressive multiple sclerosis;Ekspresja receptora Fas na limfocytach krwi obwodowej we wtórnie postȩpuja̧cej postaci stwardniena rozsianego

Polski Merkuriusz Lekarski

Volumn 14, Issue 83, 2003, Pages 421-424

  Bilińska, Małgorzata ^a   Frydecka, Irena ^a,b   Podemski, Ryszard ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

CD4; CD8 subsets; Fas receptor; Secondary progressive MS

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; LYMPHOCYTE RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; MULTIPLE SCLEROSIS; PATIENT MONITORING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; ANTIGENS, CD8; ANTIGENS, CD95; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; T-LYMPHOCYTES;

EID: 0038271881     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Alderson M.R. i wsp.: Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med., 1995, 181, 71-77.
2. Balashov K.E. i wsp.: Increased interleukin-12 production in progressive multiple sclerosis: Induction by activated CD4+ cells via CD40L. Proc. Natl. Acad. Sci. USA, 1997, 94, 599-603.
3. Bansil S. i wsp.: Serum soluble interleukin-2 receptor levels in chronic progressive, stable and steroid-treated multiple sclerosis. Acta Neurol. Scand., 1991, 84, 282-285.
4. Brocke S. i wsp.: Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigens. Nature, 1993, 365, 642-644.
5. Comabella M. i wsp.: Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest., 1998, 102, 671-677.
6. Comi C. i wsp.: Defective T cell Fas function in patients with multiple sclerosis. Neurology, 2000, 55, 921-927.
7. Confavreux C. i wsp.: Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain, 1980, 103, 281-300.
8. Dhein J. i wsp.: Autocrine T-cell suicide mediated by Apo-1 (Fas/CD95). Nature, 1995, 373, 438-441.
9. Ichikawa T. i wsp.: Increased Fas antigen on T cells in multiple sclerosis. J. Neuroimmunol., 1996, 71, 125-129.
10. Kittur S.D. i wsp.: Soluble interieukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders. Ann. Neurol., 1990, 28, 168-173.
11. Kurtzke J.F.: Rating neurologic impairment in multiple sclerosis: an expanded disability status score (EDSS). Neurology, 1983, 33, 1444-1452.
12. Lublin F.D. i wsp.: Defining the clinical course of multiple sclerosis. Results of an international survey. Neurology, 1996, 46, 907-911.
13. Morimoto C.H. i wsp.: Selective loss of the supresor-inducer T-cell subset in progressive multiple sclerosis. N. Engl. J. Med., 1987, 316, 67-72.
14. Mylawaki T. i wsp.: Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol., 1992, 149, 3753-3758.
15. Mysler E. i wsp.: The apoptosis-1/Fas proten in human systemic lupus erythematosus. J. Clin. Invest., 1994, 93, 1029-1034.
16. Nagata S. i wsp.: The Fas death factor. Science, 1995, 267, 1449-1456.
17. Nicoletti F. i wsp.: Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J. Neuroimmunol., 1996, 70, 87-90.
18. Perry V.H. i wsp.: The role of axonal pathology in MS disability. Int. MSJ., 1999, 6, 7-13.
19. Rieckmann P. i wsp.: Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology, 1994, 44, 1523-1526.
20. Rohowsky-Kochan C. i wsp.: Decreased supressor-inducer T lymphocytes in multiple sclerosis and other neurological diseases. J. Neuroimmunol., 1990, 28, 161-168.
21. Sarchielli P. i wsp.: Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. J. Neuroimmunol., 1997, 80, 76-86.
22. Semra Y.K. i wsp.: Overexpression of the apoptosis inhibitor FLIP in T cells correlates with disease activity in multiple sclerosis. J. Neuroimmunol., 2001, 113, 268-274.
23. Trotter J.L. i wsp.: Serum cytokine levels in chronic progressive multiple sclerosis: interieukin-2 levels parralel tumor necrosis factor-alpha levels. J. Neuroimmunol., 1991, 33, 29-36.
24. Weinshenker B.G. i wsp.: The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain, 1989, 112, 1419-1428.
25. Weinshenker B.G.: Natural history of multiple sclerosis. Ann. Neurol., 1994, 36, 6-11.
26. Wucherpfenning K.W. i wsp.: Molecular mimicry in T-cell mediated autoimmunity: viral peptides activate human T cell clones specific for myeline basic protein. Cell, 1995, 80, 695-705.
27. Zipp F. i wsp.: CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2. J. Neuroimmunol., 1998, 81, 168-172.
28. Zoukos Y. i wsp.: Increased expression of high affinity IL-2 receptors and beta-adrenoceptors on peripheral blood cells is associated with clinical and MRI activity in multiple sclerosis. Brain, 194, 117, 307-315.